A total of 80 institutions have reported a stake in Protalix BioTherapeutics, Inc. (NYSE:PLX) as of December 2025, according to recent 13F filings with the SEC.
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 31 Dec, 2025 | 3,647,106 | 96,078 | 2.71% | $6,564,791.00 |
| Opaleye Management Inc. | 31 Dec, 2025 | 2,478,176 | -102,380 | -3.97% | $4,460,717.00 |
| RENAISSANCE TECHNOLOGIES LLC | 31 Dec, 2025 | 1,263,300 | -52,100 | -3.96% | $2,273,940.00 |
| NORTHERN TRUST CORP | 31 Dec, 2025 | 865,708 | -36,751 | -4.07% | $1,558,274.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 830,054 | 10,277 | 1.25% | $1,494,096.00 |
| STATE STREET CORP | 31 Dec, 2025 | 585,261 | 86,714 | 17.39% | $1,053,470.00 |
| Stratos Wealth Partners, LTD. | 31 Dec, 2025 | 500,000 | 0 | 0.00% | $900,000.00 |
| VANGUARD GROUP INC | 31 Dec, 2025 | 488,552 | 24,131 | 5.20% | $879,393.00 |
| CITADEL ADVISORS LLC | 31 Dec, 2025 | 317,628 | 280,322 | 751.41% | $571,730.00 |
| JANE STREET GROUP, LLC | 31 Dec, 2025 | 289,917 | 253,417 | 694.29% | $521,851.00 |
| GOLDMAN SACHS GROUP INC | 31 Dec, 2025 | 262,809 | 111,980 | 74.24% | $473,056.00 |
| UBS Group AG | 31 Dec, 2025 | 262,520 | 72,244 | 37.97% | $472,536.00 |
| Connor, Clark & Lunn Investment Management Ltd. | 31 Dec, 2025 | 232,093 | -168,305 | -42.03% | $417,767.00 |
| Main Street Financial Solutions, LLC | 31 Dec, 2025 | 214,100 | 85,000 | 65.84% | $385,380.00 |
| Bank of New York Mellon Corp | 31 Dec, 2025 | 210,867 | 72,319 | 52.20% | $379,561.00 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 189,100 | 0 | 0.00% | $340,380.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 31 Dec, 2025 | 175,070 | 0 | 0.00% | $315,126.00 |
| COMMONWEALTH EQUITY SERVICES, LLC | 31 Dec, 2025 | 171,772 | 0 | 0.00% | $309,190.00 |
| Round Rock Advisors LLC | 31 Dec, 2025 | 155,102 | 155,102 | 0.00% | $279,184.00 |
| Diametric Capital, LP | 31 Dec, 2025 | 138,929 | -41,055 | -22.81% | $250,072.00 |